×

US FDA declines to approve Capricor’s Duchenne treatment citing unreliable trial data; shares slump

By Thomson Reuters Nov 20, 2026 | 5:44 PM

Nov 20 (Reuters) – The US Food and Drug Administration declined to approve Capricor Therapeutics’ experimental cell therapy for a fatal inherited disease that weakens muscle, the ​health regulator said on Friday, adding to a ‌string of regulatory setbacks for the biotech firm.

Capricor, whose shares fell 77% in extended trading, did not immediately respond to a Reuters request for comment.

The company was seeking approval for the therapy, known as deramiocel, ‌to ​preserve upper-limb function in Duchenne muscular ⁠dystrophy patients.

The agency said ⁠serious data integrity problems in a key clinical trial, including unauthorized changes to the analysis plan after it began, violations of rules meant to keep patients and researchers from ​knowing who got the treatment, and other protocol violations.

The FDA said the violations “compromise the reliability of the study ⁠data.” It added that the data ⁠is “not considered reliable or interpretable” as proof that ​the treatment works. It also said the treatment did not ​meet the study’s main goals.

Duchenne is a fatal genetic ‌disease that primarily affects boys and causes progressive muscle weakness, loss of mobility, heart complications and premature death.

The regulatory rejection deals a heavy blow to Capricor, threatening its lead experimental ⁠asset and clouding the company’s commercial prospects after months of efforts to salvage the application by narrowing its focus to arm ⁠and hand movement.

The ‌decision follows a nine-to-three vote in July ⁠in which the FDA’s advisers said the evidence ​presented ‌at the time did not establish deramiocel’s ​effectiveness in ⁠Duchenne-related heart disease.

In August, Capricor had submitted an amended application with 24-month data from its late-stage study, along with extra analyses, focusing specifically on upper-limb muscle function.

(Reporting by Kunal Das, Sahil Pandey and Kamal Choudhury in Bengaluru. Editing by Alan Barona ​and Perla Velasco)